arrow
G

Giacomo Ruotolo

Eli Lilly and Company
H指数:42
被引数:6,726

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unraveling the physiological impact of ANGPTL8 loss-of-function variants in humans

解析人类ANGPTL8功能缺失变异的生理影响

2026-04-290
OA
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids

接受雷特拉曲肽治疗后,循环中ANGPTL3/8浓度的降低与血清脂质的减少相平行。

2025-07-290
OAAI
Body weight reduction-associated and -unassociated changes in lipid profile in people with obesity, with or without T2D, treated with tirzepatide: post-hoc analysis of SURMOUNT-1 and SURMOUNT-2

体质量减轻相关及非相关的血脂谱变化:在伴有或不伴有T2D的肥胖人群中接受tirzepatide治疗:SURMOUNT-1和SURMOUNT-2的事后分析

2024-11-120
PRE
Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease

CETP (胆固醇酯转移蛋白) 的药理抑制作用会增加HDL (高密度脂蛋白),其中包含ApoC3和其他与冠心病高风险相关的HDL亚种

2022-02-0133
OAAI
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

双葡萄糖依赖性促胰岛素肽和胰高血糖素样肽-1受体激动剂tirzepatide可改善2型糖尿病患者与胰岛素抵抗和心血管风险相关的脂蛋白生物标志物

2020-09-15102
OAAI